Moving on from issues with the optimal patient populace, the two of us can see benefit in the multiple dose trial evaluating, for instance, one, ten and twenty five?mg of psilocybin. Such a design seems to beat several of the problems any trial of the copyright will face. The moral dilemma of equipoise would seem satisfactory for the reason that we